Drugs Made In America Acquisition Corp. - Class A Ordinary Shares, par value $0.0001 per share ("Ordinary Shares") (DMAA)

Q: What does CUSIP G2847J104 represent in this 13F holders report?

CUSIP G2847J104 is the security identifier for DMAA - Drugs Made In America Acquisition Corp. - Class A Ordinary Shares, par value $0.0001 per share ("Ordinary Shares") used to aggregate holder disclosures.

Q: How many institutions held DMAA - Drugs Made In America Acquisition Corp. - Class A Ordinary Shares, par value $0.0001 per share ("Ordinary Shares") in Q1 2026?

38 institutional investors reported DMAA - Drugs Made In America Acquisition Corp. - Class A Ordinary Shares, par value $0.0001 per share ("Ordinary Shares") for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: G2847J104

Q1 2026 13F Holders as of 31 Mar 2026

Security type / class: Equity / Class A Ordinary Shares, par value $0.0001 per share ("Ordinary Shares")
Total 13F shares: 22,514,907
Total 13F value: $236,043,075
Share change: -130,144
SEC-reported price per share: $10.48
Number of holders: 38
Value change: -$929,603
Number of buys: 10
Number of sells: 13
Shares outstanding: 24,273,426

Security key

G2847J104

Report period

Q1 2026

Institutions

Top holders

DMAA full security history Ownership snapshot Full 13F holder table Newer quarter: Q2 2026 Previous quarter: Q4 2025 Drugs Made In America Acquisition Corp. SEC filings Drugs Made In America Acquisition Corp. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP G2847J104

Newer quarter: Q2 2026 Previous quarter: Q4 2025

Recent filing periods:

Q2 2026 Q1 2026 Q4 2025 Q3 2025

Ownership snapshot

Top reported holders of DMAA - Drugs Made In America Acquisition Corp. - Class A Ordinary Shares, par value $0.0001 per share ("Ordinary Shares") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Drugs Made In America Acq...

Disclosed value leader

Drugs Made In America Acq...

Comparable rows

15/15

Latest evidence

31 Dec 2025

13D/G 3/4/5 13F Lead comparable stake: 12% 13D/G row: Drugs Made In America Acquisition LLC Showing 1-6 of 15 holder rows.

Quick read

Drugs Made In America Acquisition LLC leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Drugs Made In America Acquisition LLC's linked filing trail.

Comparable ownership Top 5

Drugs Made In America Acquisition... 12%

Polar Asset Management Partners Inc. 5.7%

Hudson Bay Capital Management LP 4.6%

Karpus Management, Inc. 10%

First Trust Capital Management L.P. 9.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Drugs Made In America Acquisition LLC	13D/G 3/4/5 10%+ Owner 13D/G 3/4/5	12%	$42,139,127 4,188,780 shares	$0	18 Feb 2025
Polar Asset Management Partners Inc.	13D/G 13F Company 13D/G 13F	5.7%	$19,114,000 1,900,000 shares	$0	31 Mar 2025
Hudson Bay Capital Management LP	13F 13D/G Company 13F 13D/G	4.6% from 13D/G	$16,357,720 3,350,000 shares mixed-class rows	—	31 Dec 2025
Karpus Management, Inc.	13F Company 13F	10%	$26,325,718 2,538,642 shares	—	31 Dec 2025
First Trust Capital Management L.P.	13F Company 13F	9.2%	$23,264,144 2,242,500 shares	—	31 Dec 2025
MIZUHO SECURITIES USA LLC	13F Company 13F	5.9%	$14,771,165 1,433,483 shares	—	31 Dec 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

22,514,907

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 value	Q1 2026 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend